Moderna Inc. (NASDAQ:MRNA) is seeing a significant rise in its stock price, thanks to positive news about its cancer therapy pipeline.
Today, Moderna's stock is up by 1.61%, reflecting growing confidence in the oncology sector. This increase adds to a week-long trend where shares have risen over 5%, contributing about $4.2 billion to its market capitalization.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$86.33B
52W high
$227.46
52W low
$22.28
1W change
+15.36%
Beta
1.09
Analyst Price Targets
Based on 23 analysts covering MRNA · as of Oct 12, 2026
Wall Street analysts forecast MRNA stock price to fall 43.3% over the next 12 months.
Consensus
Hold3.17 / 5.00
Avg. Target
C$122.67
-43.3% Upside
Previously C$121.00 on Oct 8, 2026
Current Price
C$216.25
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
81.8%
Annualized
90-Day Vol
194.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$258.53
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$229.51 | C$173.09 – C$304.33 |
| 60 trading days | C$243.59 | C$163.45 – C$363.03 |
| 90 trading days | C$258.53 | C$158.59 – C$421.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are becoming more optimistic about Moderna's future in cancer treatment, especially after promising results from its intismeran autogene therapy, which has shown potential in phase III trials for melanoma.
Moderna Gains Over $4B in Market Value This Week
The stock's recent performance highlights strong investor interest in Moderna's cancer therapies, particularly following the positive phase III results for its mRNA-based treatment.
Bull case
Moderna's inclusion in the Nasdaq-100 Index is likely to draw more institutional investment. Additionally, the ongoing NIH-backed initiative to speed up cancer-vaccine research boosts the credibility of its oncology efforts. The positive clinical results from intismeran strengthen the company's growth story.
Bear case
However, investors should stay cautious. The company's profit margin is still negative, and the competitive landscape in both oncology and respiratory vaccines could challenge its ability to maintain growth.
Advertisement
Positive Developments in Oncology
Moderna's recent gains stem from encouraging results in the phase III INTerpath-001 study of its intismeran autogene therapy, which has shown promise in improving recurrence-free survival for melanoma patients. This has renewed interest in the company's oncology pipeline, making it a key growth driver.
Market Reactions and Future Prospects
The stock's rise is also tied to its recent addition to the Nasdaq-100 Index, which is expected to boost demand from index-tracking funds. Investors are hopeful that this momentum will continue, especially as Moderna prepares to report its Q3 2026 financial results on November 6, 2026.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
